Enliven Therapeutics Inc. (ELVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has a cash flow conversion efficiency ratio of -0.034x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.84 Million) by net assets ($459.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enliven Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Enliven Therapeutics Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Enliven Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enliven Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ONESPAWORLD HLDGS DL-0001
F:ORW
|
N/A |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
0.018x |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
-0.034x |
|
Dong Yi Ri Sheng Home Decoration Group Co Ltd
SHE:002713
|
0.017x |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
-0.077x |
|
Tootsie Roll Industries Inc
NYSE:TR
|
0.068x |
|
Yelp Inc
NYSE:YELP
|
0.179x |
|
Jiangsu Cai Qin Technology Co Ltd
SHG:688182
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Enliven Therapeutics Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Enliven Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.49 Million | $-70.30 Million | -0.153x | +35.23% |
| 2024-12-31 | $309.85 Million | $-73.19 Million | -0.236x | +5.19% |
| 2023-12-31 | $245.91 Million | $-61.27 Million | -0.249x | -159.67% |
| 2022-12-31 | $-76.83 Million | $-32.08 Million | 0.418x | +333.19% |
| 2021-12-31 | $106.86 Million | $-19.13 Million | -0.179x | -77.26% |
| 2020-12-31 | $84.44 Million | $-8.53 Million | -0.101x | +86.65% |
| 2019-12-31 | $28.92 Million | $-21.88 Million | -0.757x | +49.38% |
| 2018-12-31 | $5.87 Million | $-8.78 Million | -1.494x | -48.63% |
| 2017-12-31 | $8.74 Million | $-8.79 Million | -1.005x | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more